Amyris Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Balanced Scorecard for Deeper Strategic Insight
This Amyris Balanced Scorecard Analysis gives you a clear view of the company's financial, customer, internal process, and learning and growth priorities in one structured format. The page already includes a real preview of the actual analysis, so you can see the content before buying. Purchase the full version for the complete ready-to-use report.
Benefits
Commercialization Signal
Balanced Scorecard turns Amyris's science into market proof by linking engineered-yeast milestones to launch readiness, sample-to-order conversion, and repeat buys. That mattered because Amyris's value came from saleable fermentation ingredients, and the firm entered Chapter 11 in 2023, so commercial traction mattered more than patent counts. By 2025, the key signal is still simple: no launch, no cash.
Yield Discipline
Yield Discipline matters at Amyris because the Balanced Scorecard keeps yield, titer, and throughput in one view, so strain progress is judged on both biology and factory fit. In synthetic biology, even a 1% to 2% lift in yield can move unit economics, cut feedstock cost, and signal that a strain is closer to scale. It also flags weak strains early, before low throughput turns into cash burn.
Margin Clarity
Margin clarity is critical for Amyris because the company had no 2025 operating filings after its 2023 Chapter 11 case, so the scorecard had to show unit economics fast. Tracking cost per kilogram, COGS, and plant yield tied daily operations to gross margin and cash burn. In a capital-heavy biotech model, that linkage shows whether each product is moving toward breakeven or still destroying cash.
Sustainability Proof
Balanced Scorecard captures Amyris's sustainability edge by tracking bio-based content, petroleum displacement, and lifecycle impact, not just sales. That mattered in flavors, fragrances, cosmetics, nutraceuticals, and pharmaceuticals, where buyers compare claims against measurable proof like kg CO2e per kg ingredient and feedstock substitution rates.
Market Balance
Market balance matters for Amyris because it sold into flavors, fragrances, cosmetics, nutraceuticals, and pharmaceuticals, each with different buying cycles and margin patterns. A Balanced Scorecard lets management compare adoption, pricing power, and renewal trends side by side, so weak demand in one end market does not hide strength in another. It also helps spot where contract revenue is stable versus where spot sales are more volatile. That makes capital and R&D decisions cleaner.
Amyris: Speed, Cash Control, and Scale Discipline
For Amyris, a Balanced Scorecard's main benefit was speed: it tied strain yield, launch readiness, and cash burn to the same view. Amyris filed Chapter 11 in 2023, and its 2025 status still shows no fresh operating filings, so the scorecard's value is in hard checks on unit economics. One clear rule: no commercial pull, no scale.
| Benefit | Why it mattered | Key data |
|---|---|---|
| Cash control | Tracked burn vs. scale | Chapter 11 in 2023 |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Cash Burn Gap
Balanced Scorecard can miss liquidity strain. Amyris was research-heavy and cash-hungry, and by its 2024 annual filing it had already exited as a going concern after Chapter 11, showing how debt service and funding risk can outrun nonfinancial gains. For a model that burned cash faster than it could fund R&D and scale, a scorecard without a hard liquidity test can miss the real failure point.
Scale-Up Volatility
Amyris showed how lab wins can miss at plant scale: yield swings, contamination, and bottlenecks can lift scorecard targets while unit costs stay too high. The gap got real fast; Amyris entered Chapter 11 in August 2023 after years of scale-up strain. In this case, commercial fermentation economics mattered more than lab output.
Data Gaps
Amyris's restructuring left a thin public data trail by March 2026, so Balanced Scorecard checks lean on older filings and one-off disclosures instead of current operating metrics. With no fresh 2025 operating release to anchor sales, margin, or cash-flow trends, any scorecard read is harder to verify and more exposed to stale assumptions. That weakens confidence in customer, process, and learning measures.
Portfolio Blur
Portfolio blur was a real risk for Amyris because it sold into flavors, fragrances, cosmetics, nutraceuticals, and pharmaceuticals, each with different demand and margin profiles. A single balanced scorecard can hide whether weak results came from one unit or a wider pricing, volume, or cost problem. That matters at Amyris because the company later posted severe losses and filed for Chapter 11 in 2023, so separating segment stress from company-wide issues was critical.
Partner Dependence
Amyris was highly exposed to partners: it depended on outside customers, contract manufacturers, and feedstock suppliers, so a Balanced Scorecard can look stable while the operating base is fragile. In its 2023 bankruptcy, Amyris disclosed about $1.3 billion in liabilities, showing how partner timing, supply risk, and customer concentration can hit cash fast.
That weakness is hard to see unless the model tracks supplier outages, contract renewals, and buyer mix separately. If one large customer slips or feedstock costs jump, the scorecard can miss the real risk until margins and liquidity already break.
Balanced Scorecard Missed Amyris's Cash Collapse
Balanced Scorecard also missed Amyris's cash collapse: it filed Chapter 11 in August 2023, and its 2023 filing showed about $1.3 billion in liabilities. By its 2024 annual filing, Amyris had already exited as a going concern, so noncash scorecard wins could not offset liquidity stress.
| Risk | Data |
|---|---|
| Liabilities | $1.3B |
| Chapter 11 | Aug 2023 |
| Going concern | 2024 filing |
Get Your Copy
Amyris Reference Sources
This Amyris Balanced Scorecard Analysis preview is the same document you'll receive after purchase – no changes, no sample filler. It reflects the actual report content, structure, and formatting included in the final download. Buy with confidence knowing the full version is ready to access immediately after checkout.
Frequently Asked Questions
It highlights whether the science is becoming a viable business. For Amyris, the most useful signals are fermentation yield, titer, gross margin, and repeat customer orders across ingredients. Those metrics show if engineered yeast and plant-sugar inputs are moving from research and development promise to commercial performance.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.